Aliskiren, the First Renin Inhibitor for Treating Hypertension: Reactive Renin Secretion May Limit Its Effectiveness

American Journal of Hypertension

Volumn 20, Issue 5, 2007, Pages 587-597

  Sealey, Jean E ^a   Laragh, John H ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Aliskiren; angiotensin II type 1 receptor blocker; angiotensin converting enzyme inhibitor; clinical trial; diuretic; hypertension; malignant hypertension; renin; renin inhibitor; renin angiotensin; renovascular hypertension

Indexed keywords

ALISKIREN; CAPTOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; PROPRANOLOL; RAMIPRIL; TEKTURNA; UNCLASSIFIED DRUG; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; MONOTHERAPY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN RELEASE; REVIEW; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE;

AMIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; RENIN;

EID: 34247644329     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.04.001     Document Type: Review

References (24)

1. Laragh J.H., and Sealey J.E. Renin system understanding for analysis and treatment of hypertensive patients: a means to quantify the vasoconstrictor elements, diagnose curable renal and adrenal causes, assess risk of cardiovascular morbidity, and find the best-fit drug regimen. In: Laragh J.H., and Brenner B.M. (Eds). Hypertension: Pathophysiology, Diagnosis, and Management. 2nd Ed. (1995), Raven Press, New York 1813-1836
2. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 14 (2001) 84-89 186-194, 296-304, 307-310, 397-404, 491-503, 603-609, 733-742, 837-854, 1173-1177
3. Gradman A.H., Schmeider R.E., Lins R.L., Nussberger J., Chiang Y., and Bedigian M.P. Alisiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111 (2005) 1012-1018
4. Villamil A., Chrysant S.G., Calhoun D., Schober B., Hsu H., Matrisciano-Dimichino L., and Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25 (2007) 217-226
5. Pool J.L., Schmieder R.E., Azizi M., Aldigier J.-C., Januszewicz A., Zidek W., Chiang Y., and Satlin A. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 20 (2007) 11-20
6. Oh B.-H., Mitchell J., Herron J.R., Chung J., Khan M., and Keefe D.L. Aliskiren, an oral renin inhibitor, provides dose dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 49 (2007) 1157-1163
7. Stanton A., Jensen C., Nussberger J., and O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42 (2003) 1137-1143
8. O'Brien E., Barton J., Nussberger J., Mulcahy D., Jensen C., Dicker P., and Stanton A. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker (Supplemental figures and tables can be accessed online.). Hypertension 49 (2007) 276-284
9. Physicians desk reference both edition. Thomson PDR, Montvalent 2006; p 2889.
10. Nussberger J., Gradman A.H., Schmieder R.E., Lins R.L., White W.B., Prescott M., and Chiang Y. Changes in plasma renin match the antihypertensive effects of aliskiren in patients with hypertension: placebo/irbesartan-controlled trial with the orally active renin inhibitor aliskiren (Abstract). Am J Hypertens 18 (2005) 234A
11. Azizi M., Menard J., Bissery A., Guyenne T.-T., Bura-Riviere A., Vaidyanathan S., and Camissasca R.P. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15 (2004) 3126-3133
12. Feldman D.L., Persohn E., Schutz H., Jin L., Miserendino-Molteni R., Xuan H., Zhuang S., and Zhou W. Renal localization of the renin inhibitor aliskiren (Abstract). J Clin Hypertens 8 Suppl A (2006) A80
13. Campbell Jr. W.G., Gahnem F., Catanzaro D.F., James G.D., Camargo M.J.F., Laragh J.H., and Sealey J.E. Plasma and renal prorenin/renin, renin mRNA, and blood pressure in Dahl salt-sensitive and salt-resistant rats. Hypertension 27 (1996) 1121-1133
14. Derkx F.H.M., van der Meiracker A.H., Fischli W., Admiraal P.J.J., Man in't Veld A.J., van Brummelen P., and Schalekamp M.A.D.H. Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects: an assay related artifact. Am J Hypertens 4 (1991) 602-609
15. Sealey J.E. Plasma renin activity and plasma prorenin assays. Clin Chem 37 (1991) 1811-1819
16. Drayer J.I.M., Keim H.J., Weber M.A., Case D.B., and Laragh J.H. Unexpected pressor responses to propranolol in essential hypertension. Am J Med 60 (1976) 897-903
17. Baer L., Parra-Carrilo J.Z., Radichevich I., and Williams G.S. Detection of renovascular hypertension with angiotensin II blockade. Ann Intern Med 86 (1977) 257-260
18. Egan B.M., Weder A.B., Petrin J., and Hoffman R.G. Neurohumoral and metabolic effects of short-term dietary NaCl restriction in men. Relationship to salt-sensitivity status. Am J Hypertens 4 (1991) 416-421
19. Mueller F.B., Sealey J.E., Case D.B., Atlas S.A., Pickering T.G., Pecker M.S., Preibisz J., and Laragh J.H. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 80 (1986) 633-644
20. Messerli F.H., and Re R.N. Do we need yet another blocker of the renin-angiotensin system?. J Am Coll Cardiol 49 (2007) 1164-1165
21. Buhler F.R., Laragh J.H., Baer L., Vaughan Jr. E.D., and Brunner H.R. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 287 (1972) 1209-1214
22. Buhler F.R., Laragh J.H., Vaughan Jr E.D., Brunner H.R., Gavnas H., and Baer L. Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 32 (1973) 511-522
23. Blumenfeld J.D., Sealey J.E., Mann S.J., Bragat A., Marion R., Pecker M.S., Sotelo J., August P.A., Pickering T.G., and Laragh J.H. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in noremotensive and hypertensive subjects. Amer J Hypertens 12 (1999) 451-459
24. Pickering T.G., Case D.B., Sullivan P.A., and Laragh J.H. Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise. Am J Cardiol 49 (1982) 1566-1568